MedTrace Logo

Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.

NCT07117058 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 545

Last updated 2026-03-30

No results posted yet for this study

Summary

In France today, it is estimated that one in every 850 people aged between 20 and 45 is a childhood cancer survivor (CCS), equivalent to around 40,000 to 50,000 people. Some descriptive studies have established that the diagnosis and treatment of cancer can affect psychological health. A French study published by our team in 2015 and 2020 showed that in adulthood, 40% of CCS had anxiety symptoms, a rate significantly higher than that of the general French population (25%). However, although there are validated scales for screening children for psychological disorders (anxiety, depression, etc.), there is no rapid screening tool that can be used routinely by an oncologist during consultations. So, the study aims to develop and validate a short test, which could easily be carried out systematically during follow-up consultations after childhood cancer. It would make it possible to identify people with no psychological complications and, conversely, those in whom further investigation, based on the classic reference scales for assessing psychological disorders, would be relevant.

Conditions

  • Generalized Anxiety
  • Introspective & Anxiety-Prone Patient
  • Depression, Anxiety
  • Survivors of Childhood Cancer

Interventions

DIAGNOSTIC_TEST

New rapid screening tool for anxiety and depressive disorders

New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation

DIAGNOSTIC_TEST

SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)

Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.

DIAGNOSTIC_TEST

HADS (Hospital Anxiety and Depression Scale)

Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

    lead OTHER

Principal Investigators

  • CLAIRE BERGER, MD · CHU SAINT-ETIENNE

Eligibility

Min Age
7 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-18
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117058 on ClinicalTrials.gov